HBW Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

FDA reform bill adopted Nov. 9 preserves states' safety authority over cosmetics.

This article was originally published in The Rose Sheet

Executive Summary

FDA COSMETICS-DRUGS RECORDS INSPECTION AUTHORITY GRANTED IN REFORM BILL in a provision that expands the agency's records inspection jurisdiction to over-the-counter drugs. "Cosmetic products that are also OTC drugs will...be subject to records inspection by FDA," according to a Senate/House conference committee statement released Nov. 9 after passage of the FDA reform bill by both chambers. The clause amends the Good Manufacturing Procedures (GMP) provision in the FD&C Act that authorizes the agency to inspect the manufacturing facility records of prescription drug manufacturers. Cosmetic-drug products that will be required to comply with the records inspection clause include sunscreens, acne products, dandruff shampoos and antiperspirant/deodorants.

Latest Headlines
See All
UsernamePublicRestriction

Register

RS004846

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel